Jiangsu Hengrui Medicine Co., Ltd. Overview
Pro stress-test →Jiangsu Hengrui Medicine is China's largest listed pharmaceutical company, founded in 1970 and headquartered in Lianyungang. The company researches, develops, manufactures, and commercializes innovative medicines across oncology, cardiovascular, immunological, and neuroscience therapeutic areas, operating globally with offices in the US, Europe, and Asia-Pacific.
Strategic Profile
Pro stress-test →Hengrui has established itself as a top-tier global pharmaceutical innovator, ranked among Pharma Exec's top 50 global companies for seven consecutive years and placing second globally in pipeline-scale companies. The company leverages advanced technology platforms including protein engineering and mRNA technology, with strong clinical capabilities demonstrated through multiple late-stage oncology programs addressing unmet medical needs.
Competitive Landscape
Pro stress-test →Hengrui competes with major global pharmaceutical companies in oncology and specialty care. Key competitors include Novo Nordisk, Eli Lilly, and Roche in developed markets, plus Chinese peers like BeiGene and Zai Lab. Hengrui's differentiation lies in its extensive pipeline depth, robust R&D infrastructure, and strong commercial footprint in China combined with growing international presence.
Industry Context
Jiangsu Hengrui Medicine Co., Ltd. operates in Pharmaceuticals & Biotechnology.
Key facts
Founded: 1970 · Headquarters: Lianyungang, China · Employees: 20,238 · Revenue: 27.98B CNY (2024) · Market cap: 387.53B CNY